Cancer Letters
Volume 275, Issue 1 , Pages 72-76 , 8 March 2009

A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma

  • Bin Zhou

      Affiliations

    • Laboratory of Molecular Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, PR China
    • These authors contributed equally to this work.
    • ,
  • Li Rao

      Affiliations

    • Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, PR China
    • These authors contributed equally to this work.
    • ,
  • Yi Li

      Affiliations

    • Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China
    • ,
  • Linbo Gao

      Affiliations

    • Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China
    • ,
  • Yanyun Wang

      Affiliations

    • Department of Immunology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China
    • ,
  • Yu Chen

      Affiliations

    • Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, PR China
    • ,
  • Hui Xue

      Affiliations

    • Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, PR China
    • ,
  • Yaping Song

      Affiliations

    • Laboratory of Molecular Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, PR China
    • ,
  • Ying Peng

      Affiliations

    • Department of Cardiology, West China Hospital of Sichuan University, Chengdu 610041, PR China
    • ,
  • Miao Liao

      Affiliations

    • Department of Forensic Biology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, PR China
    • ,
  • Lin Zhang

      Affiliations

    • Laboratory of Molecular Translational Medicine, West China Second University Hospital, Sichuan University, Chengdu 610041, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 28 85469033; fax: +86 28 85401825.

Received 30 July 2008 ,Revised 17 September 2008 ,Accepted 2 October 2008.

References 

  1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041–2054
  2. D.M. Parkin, S.L. Whelan, J. Ferlay, L. Teppo, D.B. Thomas, Cancer Incidence in Five Continents, vol. VIII, IARC scientific publications No. 155, 2002, pp. 1–781.
  3. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 2006;15(10):1765–1777
  4. Suarez C, Rodrigo JP, Ferlito A, Cabanillas R, Shaha AR, Rinaldo A. Tumours of familial origin in the head and neck. Oral Oncol. 2006;42(10):965–978
  5. Friborg J, Wohlfahrt J, Koch A, Storm H, Olsen OR, Melbye M. Cancer susceptibility in nasopharyngeal carcinoma families – a population-based cohort study. Cancer Res. 2005;65(18):8567–8572
  6. Friborg J, Wohlfahrt J, Melbye M. Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China. Cancer. 2005;103(1):211–212
  7. Lu SJ, Day NE, Degos L, Lepage V, Wang PC, Chan SH, et al Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature. 1990;346(6283):470–471
  8. Hildesheim A, Apple RJ, Chen CJ, Wang SS, Cheng YJ, Klitz W, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J. Natl. Cancer Inst. 2002;94(23):1780–1789
  9. Zhou X, Cui J, Macias V, Kajdacsy-Balla AA, Ye H, Wang J, et al. The progress on genetic analysis of nasopharyngeal carcinoma. Comp. Funct. Genomics. 2007;57513
  10. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell. 2004;5(5):423–428
  11. Jeyakumar A, Brickman TM, Jeyakumar A, Doerr T. Review of nasopharyngeal carcinoma. Ear Nose Throat J. 2006;85(3):168–170172–163, 184
  12. Kaye KM, Izumi KM, Kieff E. Epstein–Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 1993;90(19):9150–9154
  13. Izumi KM. Identification of EBV transforming genes by recombinant EBV technology. Semin. Cancer Biol. 2001;11(6):407–414
  14. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein–Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA. 1998;95(7):3621–3626
  15. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, et al. Transformation of Madin–Darby canine kidney (MDCK) epithelial cells by Epstein–Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene. 2000;19(14):1764–1771
  16. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80(3):389–399
  17. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, et al. Latent membrane protein 1 of Epstein–Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16(20):6131–6140
  18. Zheng H, Li LL, Hu DS, Deng XY, Cao Y. Role of Epstein–Barr virus encoded latent membrane protein 1 in the carcinogenesis of nasopharyngeal carcinoma. Cell. Mol. Immunol. 2007;4(3):185–196
  19. Yin L, Liao W, Deng X, Tang M, Gu H, Li X, et al. LMP1 activates NF-kappa B via degradation of I kappa B alpha in nasopharyngeal carcinoma cells. Chin. Med. J. 2001;114(7):718–722
  20. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 1999;45(1):7–17
  21. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 2004;13(1):35–45
  22. Rueda B, Nunez C, Lopez-Nevot MA, Paz Ruiz M, Urcelay E, De la Concha EG, et al. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease. Scand. J. Gastroenterol. 2006;41(4):420–423
  23. Oliver J, Gomez-Garcia M, Paco L, Lopez-Nevot MA, Pinero A, Correro F, et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm. Bowel Dis. 2005;11(6):576–579
  24. Li H, Gao L, Shen Z, Li CY, Li K, Li M, et al. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch. Dermatol. Res. 2008;
  25. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett. 2006;243(1):47–54
  26. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein–Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 2001;345(26):1877–1882
  27. Ho JH. An epidemiologic and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1978;4(3–4):182–198
  28. Hiyama T, Yoshihara M, Tanaka S, Chayama K. Genetic polymorphisms and head and neck cancer risk (review). Int. J. Oncol. 2008;32(5):945–973
  29. Eliopoulos AG, Young LS. LMP1 structure and signal transduction. Semin. Cancer Biol. 2001;11(6):435–444
  30. Li HP, Chang YS. Epstein–Barr virus latent membrane protein 1: structure and functions. J. Biomed. Sci. 2003;10(5):490–504
  31. Yang J, Pan WH, Clawson GA, Richmond A. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res. 2007;67(7):3127–3134
  32. Criswell TL, Arteaga CL. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J. Biol. Chem. 2007;282(44):32491–32500
  33. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res. 2004;64(18):6511–6523
  34. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001;7(5):1419–1428
  35. Lo AK, Lo KW, Tsao SW, Wong HL, Hui JW, To KF, et al. Epstein–Barr virus infection alters cellular signal cascades in human nasopharyngeal epithelial cells. Neoplasia (New York, NY). 2006;8(3):173–180
  36. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int. J. Immunogenet. 2005;32(6):401–405
  37. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J. Cancer Res. Clin. Oncol. 2007;133(11):859–866

PII: S0304-3835(08)00810-0

doi: 10.1016/j.canlet.2008.10.002

Cancer Letters
Volume 275, Issue 1 , Pages 72-76 , 8 March 2009

Article Tools

* Image Usage & Resolution